13F Holdings
中文EN

ZIVO Zivo Bioscience, Inc.

Biological Products, (No Diagnostic Substances) · OTC · SEC CIK 1101026 · Fiscal year ends 12/31

Financial factors as of 2025-09-30 (2025Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY164.5%
TTM net income YoY38.0%
TTM EPS YoY45.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin31.7%
Operating margin-4,045.7%
Net margin-4,059.7%
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-1,608.6%
ROIC (approx.)—
Asset turnover0.40x

Leverage & solvency

Liabilities / assets687.5%
Debt / equity—
Current ratio0.08x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.36x
Accruals ratio-1,025.0%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31FY20202020-12-31
Income statement
Revenue$157,220$27,650$0$0$20,000
Cost of revenue$108,268$16,040$0——
Gross profit$48,952$11,610$0——
R&D expense$3.13M$1.38M$2.24M$1.95M$3.75M
SG&A expense$10.28M$5.90M$6.49M$6.69M$4.82M
Operating income-$13.36M-$7.26M-$8.73M-$8.65M-$8.56M
Interest expense—$23,793$13,319$44,677$97,630
Net income-$13.38M-$7.78M-$8.75M-$8.76M-$9.11M
EBITDA———-$8.65M-$8.56M
EPS (basic)————-0.02
EPS (diluted)-4.23-4.60——-0.02
Dividends declared per share—3.11———
Weighted avg. shares (diluted)3.17M1.69M——406.18M
Balance sheet
Cash & equivalents$1.54M$274,380$1.80M$8.90M$137,862
Current assets$1.64M$425,377$1.90M$8.96M$167,815
PP&E, net—$0$0$0$0
Total assets$1.64M$555,715$2.12M$8.99M$220,179
Current liabilities$2.04M$2.76M$2.03M$2.95M$11.39M
Short-term debt$0$0$105,919$0—
Total liabilities$2.16M$2.76M$2.13M$2.95M$11.53M
Shareholders' equity-$514,898-$2.21M-$10,622$6.04M-$11.31M
Shares outstanding3.62M2.38M1.57M9.42M5.16M
Cash flow statement
Operating cash flow-$4.31M-$5.80M-$7.10M-$6.80M-$2.59M
Investing cash flow$0$0$0$0$0
Financing cash flow$5.58M$4.28M$0$15.57M$2.38M
Depreciation & amortization———$0$0
Stock-based compensation$1.51M$89,502-$297,653-$104,601$1.25M

Free plan shows the latest 5 periods; Pro shows all 15 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.